Nicotine and Parkinson's disease: Implications for therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Movement Disorders

• Publication date

  2008-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.21900PMID 18683238PMCID PMC4430096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022influential reference
• THE DOPAMINERGIC NIGROSTRIATAL SYSTEMAND PARKINSON'S DISEASE: MOLECULAR EVENTSIN DEVELOPMENT, DISEASE, AND CELL DEATH, AND NEW THERAPEUTIC STRATEGIES

  2007cited by this paper
• Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.

  2007cited by this paper
• Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

  2007cited by this paper
• Nigrostriatal Damage Preferentially Decreases a Subpopulation of (cid:1) 6 (cid:2) 2* nAChRs in Mouse, Monkey, and Parkinson’s Disease Striatum

  2007cited by this paper
• Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys

  2007cited by this paper
• Chronic high dose transdermal nicotine in Parkinson's disease: an open trial

  2007cited by this paper
• Guidelines on nicotine dose selection for in vivo research

  2007cited by this paper
• Pooled analysis of tobacco use and risk of Parkinson disease.

  2007cited by this paper
• Nicotine partially protects against paraquat‐induced nigrostriatal damage in mice; link to α6β2* nAChRs

  2007cited by this paper
• Smoking‐responsive juvenile‐onset Parkinsonism

  2007cited by this paper
• Chronic high dose transdermal nicotine in Parkinson ’ s disease : an open trial

  2007cited by this paper
• Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.

  2007cited by this paper
• Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.

  2007cited by this paper
• Multiple brain pathways and receptors underlying tobacco addiction.

  2007cited by this paper
• Nigrostriatal Damage Preferentially Decreases a Subpopulation of α6β2* nAChRs in Mouse, Monkey, and Parkinson's Disease Striatum

  2007cited by this paper
• Temporal relationship between cigarette smoking and risk of Parkinson disease

  2007cited by this paper
• Prevalence and treatment strategies of dyskinesia in patients with Parkinson’s disease

  2007cited by this paper
• Advances in the treatment of Parkinson's disease.

  2007cited by this paper
• Levodopa‐induced dyskinesias

  2007cited by this paper
• Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.

  2007cited by this paper
• Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine

  2006cited by this paper
• Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates

  2006cited by this paper
• Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

  2006cited by this paper
• Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

  2006cited by this paper
• Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease

  2006cited by this paper
• Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.

  2006cited by this paper
• Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

  2006cited by this paper
• Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.

  2006cited by this paper
• Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle.

  2006cited by this paper
• Neuroprotection for Parkinson's disease.

  2006cited by this paper
• Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle

  2006cited by this paper
• Diagnosis and treatment of Parkinson disease: molecules to medicine.

  2006influential reference
• Striatal α6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy

  2006cited by this paper
• Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia

  2006cited by this paper
• Opioids and motor complications in Parkinson's disease.

  2006cited by this paper
• Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates

  2006cited by this paper
• Novel pharmacological targets for the treatment of Parkinson's disease

  2006cited by this paper
• Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

  2005cited by this paper
• Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.

  2005cited by this paper
• Why does the rapid delivery of drugs to the brain promote addiction?

  2005cited by this paper
• Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia

  2005cited by this paper
• Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA

  2005cited by this paper
• Nondopaminergic mechanisms in levodopa‐induced dyskinesia

  2005cited by this paper
• Desensitized nicotinic receptors in brain.

  2005cited by this paper
• Decrease in α3*/α6* Nicotinic Receptors but Not Nicotine-Evoked Dopamine Release in Monkey Brain after Nigrostriatal Damage

  2005cited by this paper
• Desensitization of nicotinic ACh receptors: shaping cholinergic signaling.

  2005cited by this paper
• Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases : An autoradiography study using [125I]α-conotoxinMII in the striatum and thalamus

  2005cited by this paper
• Smokeless tobacco use and the risk of Parkinson's disease mortality

  2005cited by this paper
• The short-term effect of nicotine chewing gum in patients with parkinson's disease

  2005cited by this paper
• Family-based case-control study of cigarette smoking and Parkinson disease

  2005cited by this paper
• Nicotine: from molecular mechanisms to behaviour.

  2005cited by this paper
• Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy

  2005cited by this paper
• The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay.

  2005cited by this paper
• Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.

  2005cited by this paper
• Expression of Nigrostriatal α6-Containing Nicotinic Acetylcholine Receptors Is Selectively Reduced, but Not Eliminated, by β3 Subunit Gene Deletion

  2005cited by this paper
• Levodopa-induced dyskinesia in Parkinson’s disease

  2005cited by this paper
• Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus.

  2005cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment

  2004cited by this paper
• Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.

  2004cited by this paper
• Presynaptic ionotropic receptors and control of transmitter release

  2004cited by this paper
• Smoking and Parkinson's disease: Systematic review of prospective studies

  2004cited by this paper
• Loss of α‐conotoxinMII‐ and A85380‐sensitive nicotinic receptors in Parkinson's disease striatum

  2004cited by this paper
• Multiple risk factors for Parkinson's disease.

  2004cited by this paper
• Smoking, nicotine and Parkinson's disease.

  2004cited by this paper
• Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.

  2004cited by this paper
• Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.

  2004cited by this paper
• The scientific basis for the current treatment of Parkinson's disease.

  2004cited by this paper
• Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.

  2004cited by this paper
• Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.

  2003cited by this paper
• Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.

  2003cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease

  2003cited by this paper
• The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors.

  2003cited by this paper
• Nicotine protects rat brain mitochondria against experimental injuries.

  2003cited by this paper
• A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD

  2003cited by this paper
• Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease

  2003cited by this paper
• Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]α‐bungarotoxin binding sites in the brain of Macaca mulatta

  2003cited by this paper
• Subunit Composition of Functional Nicotinic Receptors in Dopaminergic Neurons Investigated with Knock-Out Mice

  2003cited by this paper
• The β3 Nicotinic Receptor Subunit: A Component of α-Conotoxin MII-Binding Nicotinic Acetylcholine Receptors that Modulate Dopamine Release and Related Behaviors

  2003cited by this paper
• A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease

  2002cited by this paper
• Smoking and Parkinson’s disease in twins

  2002cited by this paper
• Desensitization of neuronal nicotinic receptors.

  2002cited by this paper
• Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra

  2002cited by this paper
• Transdermal nicotine in PD : A randomized , double-blind , placebo-controlled study

  2002cited by this paper
• Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.

  2002cited by this paper
• The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

  2002cited by this paper
• Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.

  2002cited by this paper
• Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.

  2002cited by this paper
• Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure.

  2002cited by this paper
• Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure.

  2002cited by this paper
• Identification of the Nicotinic Receptor Subtypes Expressed on Dopaminergic Terminals in the Rat Striatum

  2002cited by this paper
• Direct evidence that release‐stimulating α7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals

  2002cited by this paper
• Nicotine addiction: the possible role of functional upregulation.

  2002cited by this paper
• Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture.

  2002cited by this paper
• Cholinergic interneuron characteristics and nicotinic properties in the striatum.

  2002cited by this paper
• Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism.

  2002cited by this paper
• Distribution and Pharmacology of α6-Containing Nicotinic Acetylcholine Receptors Analyzed with Mutant Mice

  2002cited by this paper
• Transdermal nicotine in PD

  2001cited by this paper

• The Effects of Nicotine on Parkinson's Disease: A Systematic Review and Meta-Analysis of Experimental Evidence

  2026cites this paper
• Chronic nicotine reduces nigral dopaminergic activity and remodels pedunculopontine cholinergic subpopulations

  2026cites this paper
• Investigating the Potential Roles of Environmental Exposures on the Pathology of Amyotrophic Lateral Sclerosis by Overlap Analysis

  2025cites this paper
• The role of BDNF/PI3K/AKT/Nrf2 signaling in nicotine's protective effects against MPTP-induced Parkinson's disease.

  2025cites this paper
• Dopaminergic Neuron‐Specific Tfam Knockout Links Inter‐Organelle Miscommunication to Early‐Onset Parkinsonism

  2025cites this paper
• Adiphenine Alleviates Impulsive‐Like Behaviors in Aged Mice by Inhibiting Nicotinic Acetylcholine Receptors

  2025cites this paper
• Nicotine Therapy for Parkinson’s Disease: A Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease

  2025cites this paper
• Shared pathogenic mechanisms of Parkinson's disease and ulcerative colitis: α7 nicotinic acetylcholine receptor as a potential therapeutic target.

  2025cites this paper
• In silico analysis of nicotine’s molecular targets in Parkinson’s disease

  2025cites this paper
• The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease

  2025cites this paper
• Significance of nicotine and nicotinic acetylcholine receptors in Parkinson’s disease

  2025cites this paper
• Effects of nicotine on catecholaminergic neurotransmission in a premotor stage model of Parkinson’s disease

  2025cites this paper
• Exercise Strategies for Parkinson Disease Management

  2025cites this paper
• Associations of the Life’s Essential 8 with Parkinson’s disease: a population-based study

  2025cites this paper
• From cigarettes to compulsions: a longitudinal study in de novo Parkinson's disease

  2025cites this paper
• Parkinson’s Disease is Predominantly a Genetic Disease

  2024cites this paper
• Nicotine is an Immunosuppressant: Implications for Women's Health and Disease.

  2024cites this paper
• Insights into Crystallization of Neuronal Nicotinic α4β2 Receptor in Polarized Lipid Matrices

  2024cites this paper
• Assessing Therapeutic Value and Side Effects of Key Botanical Compounds for Optimized Medical Treatments

  2024cites this paper
• Synaptic Vesicle Glycoprotein 2C: a role in Parkinson’s disease

  2024cites this paper
• Literature Review on Nicotine’s Role in Human Health

  2024cites this paper
• Clearing the Smoke: What Protects Smokers from Parkinson’s Disease?

  2024influential citation
• Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.

  2023cites this paper
• ՊԱՐԿԻՆՍՈՆԻ ՀԻՎԱՆԴՈՒԹՅԱՄԲ ԲՈՒԺԱՌՈՒՆԵՐԻ ՇԱՐԺՈՂԱԿԱՆ ԽԱՆԳԱՐՈՒՄՆԵՐԻ ԽՈՐԱՑՈՒՄԸ` ՊԱՅՄԱՆԱՎՈՐՎԱԾ ՆԻԿՈՏԻՆԻ (ԾԽԱԽՈՏԻ) ԸՆԴՈՒՆՄԱՆ ԴԱԴԱՐԵՑՄԱՄԲ

  2023cites this paper
• Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

  2023cites this paper
• Nicotine-mediated effects in neuronal and mouse models of synucleinopathy

  2023cites this paper
• Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease

  2023cites this paper
• Lynx1 and the family of Endogenous Mammalian Neurotoxin-Like Proteins and their Roles in Modulating nAChR Function.

  2023cites this paper
• Nicotine's effect on cognition, a friend or foe?

  2023cites this paper
• Nanotherapeutics a promising approach for treatment of Parkinson’s disease

  2022cites this paper
• Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects

  2022cites this paper
• The impact of cigarette smoking and nicotine on traumatic brain injury: a review

  2022cites this paper
• Use of tobacco purge in a therapeutic community for the treatment of substance use disorders

  2022cites this paper
• Cigarette Smoking, nicotine and Parkinson’s disease: Controversies in clinical trials data and medical practice.

  2022cites this paper
• Characteristics of Cognitive Impairment and Their Relationship With Total Cerebral Small Vascular Disease Score in Parkinson’s Disease

  2022cites this paper
• A review of the primary nutritional and environmental factors associated with Parkinson’s disease

  2021cites this paper
• Emerging roles of NAC transcription factor in medicinal plants: progress and prospects

  2021cites this paper
• Central Pain in Parkinson's Disease: Behavioral and Cognitive Characteristics

  2021cites this paper
• Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment

  2021cites this paper
• Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels

  2021cites this paper
• Molecular insights into the benefits of nicotine on memory and cognition

  2021cites this paper
• Nicotine induces morphological and functional changes in astrocytes via nicotinic receptor activity

  2021cites this paper
• Regulators of cholinergic signaling in disorders of the central nervous system

  2021cites this paper
• The protective role of cigarette smoking against Parkinson's disease via moderation of the interaction between iron deposition in the nigrostriatal pathway and clinical symptoms.

  2021cites this paper
• Nicotine Has a Therapeutic Window of Effectiveness in a Drosophila melanogaster Model of Parkinson's Disease

  2021cites this paper
• Prospects of using bioactive compounds in nanomaterials surface decoration and their biomedical purposes

  2021cites this paper
• Potential applications of nanomedicine for treating Parkinson's disease

  2021cites this paper
• Machine Learning Neuroprotective Strategy Reveals a Unique Set of Parkinson Therapeutic Nicotine Analogs

  2020cites this paper
• Disease modification trials in parkinsons disease: A Review Disease modification trials in parkinsons disease: A Review

  2020cites this paper
• Parkinson’s Disease: Possible Mechanisms for Nutritional Approaches

  2020cites this paper
• Therapeutic approaches to cholinergic deficiency in Lewy body diseases

  2020cites this paper
• Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders

  2020cites this paper
• Co-occurring WARS2 and CHRNA6 mutations in a child with a severe form of infantile parkinsonism.

  2020cites this paper
• Activation of α7‐nAChRs protects SH‐SY5Y cells from 1‐methyl‐4‐phenylpyridinium‐induced apoptotic cell death via ERK/p53 signaling pathway

  2019cites this paper
• Aldehyde adducts inhibit 3,4‐dihydroxyphenylacetaldehyde‐induced &agr;‐synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy

  2019cites this paper
• Calcium-Handling Defects and Neurodegenerative Disease.

  2019cites this paper
• Novel computational deep learning strategy for neuroprotection identification reveals unique set of nicotine analogs as potential therapeutic compounds against Parkinson’s disease

  2019cites this paper
• The Drosophila Model: Exploring Novel Therapeutic Compounds against Neurodegenerative Diseases

  2019cites this paper
• Sex differences in smoking, alcohol consumption, and risk of Parkinson's disease: A nationwide cohort study.

  2019cites this paper
• Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells

  2018cites this paper
• Effects of overexpression of jasmonic acid biosynthesis genes on nicotine accumulation in tobacco

  2018cites this paper
• The Role of Human α7-Nicotinic Acetylcholine Receptors in Mediating Neuroprotective Action of Curcumin

  2018cites this paper
• A two-dimensional pyrolysis process to concentrate nicotine during tobacco leaf bio-oil production

  2018cites this paper
• Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery

  2018cites this paper
• Recent advances in treating Parkinson’s disease

  2017cites this paper
• Cyclosomatostatin-Induced Catalepsy in the Aged Wistar Rats: Inhibition by Nicotine

  2017cites this paper
• Revisiting nicotine’s role in the ageing brain and cognitive impairment

  2017cites this paper
• Nicotine from cigarette smoking and diet and Parkinson disease: a review

  2017cites this paper
• MeCP2‐deficient mice have reduced &agr;4 and &agr;6 nicotinic receptor mRNA and altered behavioral response to nicotinic agonists

  2017cites this paper
• Current and experimental treatments of Parkinson disease: A guide for neuroscientists

  2016cites this paper
• Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

  2016cites this paper
• Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

  2016cites this paper
• Cortico-Striatal, Cognitive-Motor Interactions Underlying Complex Movement Control Deficits

  2016cites this paper
• Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits.

  2015cites this paper
• Genetic Factors for Enhancement of Nicotine Levels in Cultivated Tobacco

  2015cites this paper
• HUBUNGAN ANTARA MEROKOK DENGAN PENYAKIT PARKINSON DI RSUD PROF. DR. MARGONO SOEKARJO PURWOKERTO

  2015cites this paper
• Adverse Effects and Pharmacological Management of Newer Antidepressants - Focusing on Common but Under-Recognized Adverse Effect -

  2014cites this paper
• 새로운 항우울제의 부작용과 약물학적 처치

  2014cites this paper
• The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk

  2014cites this paper
• CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking.

  2014cites this paper
• Smoking and outcome of traumatic brain injury

  2014cites this paper
• Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

  2014cites this paper
• Enhanced synthesis and release of dopamine in transgenic mice with gain‐of‐function α6* nAChRs

  2014cites this paper
• Study of the Protective Effect of Alcohol , Coffee , and Cigarette Consumption on Parkinson Disease Risk

  2014cites this paper
• A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking

  2014cites this paper
• Synthesis of 1-substituted epibatidine analogues and their in vitro and in vivo evaluation as α4β2 nicotinic acetylcholine receptor ligands

  2014cites this paper
• TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

  2013cites this paper
• Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

  2013cites this paper
• Effect of Nicotine on the Pharmacokinetics of Levodopa

  2013cites this paper
• Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease

  2013cites this paper
• Nicotine promotes survival of cells expressing amyloid precursor protein and presenilin: implication for Alzheimer's disease.

  2013cites this paper
• Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease

  2013cites this paper
• Nicotinic acetylcholine receptors: from basic science to therapeutics.

  2013cites this paper
• Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease

  2012cites this paper
• Nicotine as a potential neuroprotective agent for Parkinson's disease

  2012cites this paper
• Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease

  2012cites this paper
• A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease

  2012cites this paper
• Cholinergic Modulation of Locomotion and Striatal Dopamine Release is Mediated by α 6 α 4 * Nicotinic Acetylcholine Receptors

  2012cites this paper
• Transcriptional Regulation of Alpha-synuclein by GATA2 in Substantia Nigra

  2012cites this paper